Prevention just became fundable

Why the money is finally moving toward keeping people well, and what it means if you're building in prevention or ageing.

For most of my career, prevention has been something everyone agrees with and yet, no one funds. Applauded in principle, starved in practice. Every health conference has a keynote about prevention. Every white paper concludes with it. Then the budgets are written, and the money goes where it always goes, to treating people once they are already ill.

That is changing now, and faster than most people working in health have registered. Not because we suddenly discovered that prevention works; we have known that for decades. It is changing because, for the first time, the money has a reason to move.

The signal

Two things happened recently that would have been unthinkable five years ago.

Y Combinator - the most-watched signal in early-stage technology named "AI for the Aging Population" as one of the largest, most underserved markets in the world, and put out an open call for founders to build there. When YC points, capital follows. It is about as close to a starting gun as this industry has.

At the same time, China is directing policy and capital into healthy ageing at national scale, treating its ageing population not only as a cost to absorb but as an industry to build - the silver economy. By 2035 it will have around 400 million people over 60.

Put those alongside the demographics everyone already knows, one in five people in the UK and USA over 65 by 2030, with nowhere near the capacity to care for them, and you have the two largest engines in the world, private capital and the state, moving in the same direction at the same time. When that happens, something stops being a trend and becomes a thesis.

Why it took so long: the wrong-pocket problem

If prevention is such an obvious good, why has it been so hard to fund? The answer is not a lack of will, evidence, good intentions, rather can be more accurately attributed to lack of structure.

The institution that pays for prevention is rarely the one that captures the saving. An employer funds a workplace health programme; the health system banks the avoided admissions, years later. An insurer funds early detection; the person stays well for a decade and the benefit lands with a pension scheme, or the state, or a different insurer entirely. A founder builds a genuinely good preventative product and discovers there is no one whose budget it fits, because almost every budget in the system is built around treating illness that has already arrived.

No single entity in that chain is behaving irrationally. Each is simply declining to pay for a benefit that shows up in someone else's accounts, in a future quarter, on a line they will never be measured against. The failure is architectural: value is created in one place and captured in another, with no mechanism to move it between them.

I have watched this from the inside for fifteen years, building a healthtech business into workplaces, sitting on a global health accreditation advisory board, and now advising founders trying to sell prevention into systems that were never designed to buy it. The pattern is always the same. The science is rarely the blocker. The wrong pocket is.

What changes when prevention becomes fundable

When capital finally arrives, the constraint moves, and this is the part most founders miss.

For years, the hard question in prevention was "can you prove it works?" Evidence was the bottleneck. Now that capital has decided prevention is a market, the bottleneck shifts. The new question is "can you build a business the buyer will actually pay for?" A clinically excellent product is now necessary, and no longer sufficient.

The deciding questions become commercial ones. Which buyer feels the cost of the problem today, not in ten years? On whose budget does your solution sit, and is that the same budget that captures the benefit? How do you price it so the pocket that pays is also the pocket that gains? What does that specific buyer need to see, on a balance sheet, not in a clinical paper, before they can say yes?

This is exactly why I built VITAL, and it is most of what I do now: taking a proven product and building the commercial architecture around it so the system will pay for it - the buyer, the proof they need, the pricing that aligns incentives, and the route to a signed contract. That is structural work, and it is where most prevention companies either break through or quietly stall.

What I'd ask, if you're building here

Three questions will tell you quickly whether your commercial engine is ready for the capital that is coming.

Who actually pays for your product, and is it the same entity that captures the benefit? If those are different pockets, you have a pricing and positioning problem to solve before you have a sales problem.

Are you positioned as a health product hoping to be bought, or as a commercial answer to a cost your buyer is already carrying? The second gets signed. The first gets admired.

And what would your lead buyer need to see before they could justify the spend to the person they answer to? If you cannot name it, that is the first thing to build.

The window

The prevention economy is no longer a moral case waiting for the world to catch up. It is becoming a commercial one, with real capital behind it, and the founders who win the next decade will be the ones who understand the economics, not only the science.

That window is open now. It will reward the companies that are commercially ready when the money arrives, and pass over the ones still treating prevention as a cause rather than a business.

If you are building here and the commercial engine isn't yet matching the product, reply to this email or drop me a line. It is the work I do best, and there has never been a better time to be doing it.

With purpose,

Sara